文献速递银屑病与炎症性皮肤病

古塞奇尤单抗对比阿达木单抗治疗中重度银屑病:VOYAGE 2 III期试验

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
PubMed 文献 · J Am Acad Dermatol · 2017-01-02

VOYAGE 2是一项III期双盲随机对照试验,纳入中重度银屑病患者,比较古塞奇尤单抗与安慰剂及阿达木单抗的疗效与安全性,并评估随机撤药后再治疗及阿达木单抗无应答者转换治疗。结果显示古塞奇尤单抗在16周和24周疗效优于对照,维持治疗应答持久,阿达木单抗无应答者转换后66.1%在第48周达到PASI 90,安全性各组相当。

要点

  • 古塞奇尤单抗16周IGA 0/1达84.1%、PASI 90达70.0%,显著优于安慰剂。
  • 古塞奇尤单抗在16周和24周多个疗效终点优于阿达木单抗(P<.001)。
  • 阿达木单抗无应答者转换古塞奇尤单抗后66.1%第48周达PASI 90。

核心结论

  • 古塞奇尤单抗是中重度银屑病高效且耐受良好的维持治疗药物,对阿达木单抗无应答者亦有效。

研究设计与样本

  • III期双盲、安慰剂和阳性对照随机撤药再治疗试验,患者随机分为古塞奇尤单抗100mg组(n=496)、安慰剂→古塞奇尤单抗组(n=248)和阿达木单抗组(n=248)。
  • 第28周时,古塞奇尤单抗组PASI 90应答者再随机接受古塞奇尤单抗或安慰剂(应答丧失后给予古塞奇尤单抗)。

主要发现

  • 第16周,古塞奇尤单抗组IGA 0/1应答率为84.1%,安慰剂组为8.5%;PASI 90应答率为70.0%,安慰剂组为2.4%(共同主要终点)。
  • 第16周(IGA 0/1、PASI 75、PASI 90)和第24周(IGA 0/1和0、PASI 90、PASI 100),古塞奇尤单抗优于阿达木单抗(P<.001)。
  • 第28至48周,古塞奇尤单抗维持治疗组应答持久性优于撤药组(P<.001)。
  • 阿达木单抗无应答者转换古塞奇尤单抗后,66.1%在第48周达到PASI 90。
  • 古塞奇尤单抗改善了患者报告结局,各组不良事件相当。

关键数值与推荐

  • 第16周共同主要终点:IGA 0/1应答率古塞奇尤单抗84.1% vs 安慰剂8.5%;PASI 90应答率70.0% vs 2.4%。
  • 古塞奇尤单抗对比阿达木单抗在多项终点优效(P<.001)。
  • 阿达木单抗无应答者转换古塞奇尤单抗后第48周PASI 90应答率66.1%。

临床怎么用

  • 古塞奇尤单抗可作为中重度银屑病的高效维持治疗选择。
  • 对阿达木单抗应答不佳者,可考虑转换古塞奇尤单抗治疗。

局限性

  • 仅1年随访,再治疗数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody, was efficacious in psoriasis. OBJECTIVE: We sought to assess efficacy and safety of guselkumab in moderate to severe psoriasis versus placebo and adalimumab, including interrupted treatment and switching adalimumab nonresponders to guselkumab. METHODS: Patients were randomized to guselkumab 100 mg (weeks 0 and 4, then every 8 weeks; n = 496); placebo→guselkumab (weeks 0, 4, and 12 then guselkumab at weeks 16 and 20; n = 248); or adalimumab (80 mg week 0, then 40 mg week 1, and every 2 weeks through week 23; n = 248). At week 28, guselkumab 90% or greater improvement in Psoriasis Area and Severity Index (PASI) score from baseline (PASI 90) responders were rerandomized to guselkumab or placebo with guselkumab after loss of response. Placebo→guselkumab responders and adalimumab responders received placebo, then guselkumab after loss of response. Nonresponders received guselkumab. RESULTS: At week 16, more patients receiving guselkumab achieved an Investigator Global Assessment (IGA) score 0/1 (cleared/minimal) (84.1% vs 8.5%) and PASI 90 (70.0% vs 2.4%) versus placebo (coprimary end points). Guselkumab was superior to adalimumab at week 16 (IGA score 0/1, 75% or greater improvement in PASI score from baseline, and PASI 90) and week 24 (IGA score 0/1 and 0, PASI 90, 100% improvement in PASI score from baseline) (P < .001). From weeks 28 to 48, better persistence of response was observed in guselkumab maintenance versus withdrawal groups (P < .001). Of adalimumab nonresponders who switched to guselkumab, 66.1% achieved PASI 90 at week 48. Guselkumab improved patient-reported outcomes. Adverse events were comparable among groups. LIMITATIONS: One-year follow-up limits retreatment data. CONCLUSIONS: Guselkumab is a highly effective, well-tolerated, maintenance therapy, including in adalimumab nonresponders.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017. PMID: 28057361. doi:10.1016/j.jaad.2016.11.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。